about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

'Bio­hack­er' Tray­wick ac­ci­den­tal­ly drowned, of­fi­cial con­firms

7 years ago
People

What's BIO and PhRMA do­ing to ad­dress sex­u­al ha­rass­ment? Sen­a­tor Mur­ray wants to know

7 years ago
Pharma

An­drew Rit­ter gath­ers the reins as his com­pa­ny preps PhI­II; Sol­id Bio co-founder Gi­lad Hay­eem re­tires

7 years ago
Peer Review

Three years lat­er the FDA fi­nal­ly lifts its hold on Ap­tose drug, set­ting the stage for a re­turn to PhIb

7 years ago
Pharma

C-Bridge hands Nu­ance Biotech $35M, open­ing doors to more Chi­na li­cens­ing deals

7 years ago
Financing
R&D

As­traZeneca, Mer­ck score a block­buster ad­vance as Lyn­parza comes through in front­line ovar­i­an can­cer

7 years ago
R&D

Roche bags full con­trol of Foun­da­tion Med­i­cine in $2.4B fol­low-up buy­out

7 years ago
Deals
Pharma

Johns Hop­kins spin­out Wind­MIL grabs $32.5M to fu­el its work on a next-gen ap­proach to cell ther­a­py

7 years ago
Financing

Aim­mune signs Jayson Dal­las on to suc­ceed re­tir­ing CEO; Ed­uar­do Bra­vo leaves TiGenix in fi­nal chap­ter of Take­da ...

7 years ago
Peer Review

Ver­ri­ca Phar­ma bankrolls PhI­II with a $75M IPO raise for lead skin drug

7 years ago
Financing

GSK, Vi­iV of­fer sneak peek of PhI­II da­ta on in-house two-drug HIV com­bo, tout­ing non-in­fe­ri­or­i­ty

7 years ago
R&D

This ex­trav­a­gant par­ty dur­ing #BIO18 fea­tured top­less dancers, and in­dus­try lead­ers are not pleased

7 years ago
Pharma

Cel­lec­tis, ris­ing star Al­lo­gene de­sign an 'all-in-one' CAR con­struct with em­bed­ded safe­ty switch as the new part­ners ...

7 years ago
Discovery

Promi­nent can­cer bi­ol­o­gist In­der Ver­ma re­signs from Salk in wake of sex­u­al ha­rass­ment al­le­ga­tions

7 years ago
People

Bit­ter­ly op­posed old guard at Take­da wages a last-ditch fight to block 'for­eign blood­'s' $62B Shire buy­out

7 years ago
Deals

Ru­bius snaps up No­var­tis vet Pablo Cagnoni as CEO; MiMedx dumps two ex­ecs fol­low­ing in­ter­nal in­ves­ti­ga­tion

7 years ago
Peer Review

Di­a­betes gi­ant No­vo said to con­sid­er up to 3,000 lay­offs as US pric­ing storms gath­er: re­port

7 years ago
R&D
Pharma

Gates Foun­da­tion sets up biotech-like in­sti­tute in hands-on ef­fort to spur drug de­vel­op­ment for ne­glect­ed dis­eases

7 years ago
R&D
Pharma

Man­u­fac­tur­ing ex­perts at Hangzhou Just Bio­ther­a­peu­tics bank $35M for stealthy R&D in Chi­na and the US

7 years ago
Financing
China

Eye­ing NDA for its di­a­betes drug, Hua Med­i­cine knocks at HKEX's door with an IPO ap­pli­ca­tion

7 years ago
Financing
China

Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

7 years ago
R&D
Pharma

Ar­a­vive merges with strug­gling Ver­sar­tis, gain­ing ac­cess to Nas­daq; Si­lence Ther­a­peu­tics CEO Ali Mor­taza­vi leaves the ...

7 years ago
News Briefing

Vaxart re­ports PhII de­feat for a lega­cy an­tivi­ral from Avi­ra­gen — shares slide

7 years ago
R&D

Ex-Gilead R&D chief Bischof­berg­er starts over as CEO of Kro­nos Bio; Sue Ma­ho­ny steps down from Lil­ly On­col­o­gy

7 years ago
Peer Review
First page Previous page 115116117118119120121 Next page Last page
A service from the Financial Times